Categories Earnings, Health Care

Regeneron Pharmaceuticals (NASDAQ: REGN): Q3 2019 Earnings Snapshot

— Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter 2019 adjusted earnings of $6.67 per share versus $6.36 per share expected.

— Total revenues grew by 23% to $2.05 billion versus $1.99 billion expected. Eylea sales increased by 16% to $1.19 billion.

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Review

— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.

— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.

— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.

— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

MU Earnings: Micron’s Q4 profit declines but beats estimates

Micron Technology Inc. (NASDAQ: MU) Thursday said its fourth-quarter profit declined from last year, hurt by a sharp fall in revenues. Earnings, however, beat the market’s projection. On an adjusted

What are Philip Morris’ (PM) anticipations for the near term?

Shares of Philip Morris International Inc. (NYSE: PM) were down 1% on Thursday. The stock has dropped over 9% year-to-date. Although the tobacco industry has felt the pinch of inflation,

Key highlights from CarMax (KMX) Q2 2023 earnings results

CarMax, Inc. (NYSE:KMX) reported second quarter 2023 earnings results today. Net revenues rose 2% year-over-year to $8.1 billion. Net earnings were $125.9 million, or $0.79 per share, compared to $285.2 million,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top